Nowacka Agnieszka, Śniegocki Maciej, Ziółkowska Ewa
Department of Neurosurgery, Collegium Medicum in Bydgoszcz, Nicolas Copernicus University in Toruń, Ul. Curie Skłodowskiej 9, 85-094 Bydgoszcz, Poland.
Department of Pediatrics, School of Medicine, Washington University in St. Louis, St. Louis, MO 63110, USA.
Antioxidants (Basel). 2025 Sep 15;14(9):1121. doi: 10.3390/antiox14091121.
Glioblastoma (GB) is an aggressive and treatment-resistant primary brain tumor with a dismal prognosis. Increasing evidence implicates oxidative stress as a central driver of its pathogenesis, progression, and resistance to therapy. The dynamic interplay between oxidative stress and antioxidant mechanisms is fundamental to understanding GBM biology and shaping novel therapeutic approaches. This review synthesizes current knowledge on the multifaceted role of redox biology in glioblastoma, highlighting the molecular mechanisms through which oxidative stress influences tumor proliferation, survival, immune evasion, and metabolic adaptation. Particular focus is given to the tumor microenvironment, hypoxia-driven reactive oxygen species, redox-regulating enzymes, and the immunosuppressive conditions fostered by oxidative stress. Antioxidants, in this context, demonstrate a dual role: while they can mitigate oxidative damage, their effects on cancer cells and treatment outcomes vary depending on the therapeutic setting. We further examine emerging strategies that target oxidative pathways, including small-molecule inhibitors, redox-modulating agents, and combinatorial approaches with standard treatments, while also addressing the complexities posed by antioxidant interventions. Preclinical and clinical findings are reviewed to underscore both the opportunities and challenges of exploiting redox vulnerabilities in GB. Ultimately, a deeper understanding of oxidative stress dynamics and antioxidant regulation may guide the development of innovative therapies that overcome resistance and improve outcomes for patients facing this devastating malignancy.
胶质母细胞瘤(GB)是一种侵袭性强且对治疗耐药的原发性脑肿瘤,预后不佳。越来越多的证据表明氧化应激是其发病机制、进展及治疗耐药的核心驱动因素。氧化应激与抗氧化机制之间的动态相互作用对于理解胶质母细胞瘤生物学特性及形成新的治疗方法至关重要。本综述综合了当前关于氧化还原生物学在胶质母细胞瘤中多方面作用的知识,强调了氧化应激影响肿瘤增殖、存活、免疫逃逸及代谢适应的分子机制。特别关注肿瘤微环境、缺氧驱动的活性氧、氧化还原调节酶以及氧化应激所促成的免疫抑制状态。在此背景下,抗氧化剂呈现出双重作用:虽然它们可以减轻氧化损伤,但其对癌细胞和治疗结果的影响因治疗环境而异。我们进一步研究了针对氧化途径的新兴策略,包括小分子抑制剂、氧化还原调节剂以及与标准治疗的联合方法,同时也探讨了抗氧化剂干预所带来的复杂性。对临床前和临床研究结果进行了综述,以强调在胶质母细胞瘤中利用氧化还原脆弱性的机遇和挑战。最终,对氧化应激动态和抗氧化调节的更深入理解可能会指导创新疗法的开发,这些疗法能够克服耐药性并改善面对这种毁灭性恶性肿瘤患者的治疗结果。